Chengde Lolo is a monopoly-style cash cow in the almond milk category: its flagship single product accounts for 94% of revenue, gross margin is 47.9% (2026H1), it operates on payment-before-delivery terms with virtually no receivables, and its non-recurring net profit held steady on a plateau of RMB 620–660 million from 2023 to 2025. At the current price of RMB 8.22, the stock trades at 12.6x PE (TTM) (6th percentile of the past 5 years) with a 6.08% dividend yield — the price is already close to the Earnings Power Value (EPV) under a zero-growth assumption, with dividends and asset value providing downside support, while upside requires a catalyst. Two major constraints: first, RMB 2.871 billion of deposits have long been parked at Wanxiang Finance, an affiliate of the controlling shareholder, yielding only about 1.28% (below the company's own borrowing rate) — this governance discount is the core drag on the valuation midpoint; second, the +11.3% growth in 2026H1 contains flattery from the Spring Festival timing mismatch — excluding it, Q2 organic growth was only about +4.9%, and the long-term demand contraction of the category (almond milk sales volume -7.75% in 2025) has not been disproven. Overall judgment: good quality, reasonably but only modestly cheap price (margin of safety approx. +5%), and a lack of upward catalysts until the governance discount is resolved — hence a Neutral rating with a wait-and-see stance. This could be upgraded to Positive if the Q3 report confirms growth continuation and the Chun'an plant's October production start is delivered as planned.
Key upcoming changes: ① Operations are shifting from a double decline in 2025 (revenue -3.46%, net profit attributable to parent -5.87%) to a recovery in 2026H1 (revenue +11.29%, net profit attributable to parent +15.28%); the Q3 report (expected late October 2026) will be the validation point for growth continuation; ② Southern markets are shifting from "remote reach from the northern base" to localized production — the first phase of the Chun'an 150,000-ton base, two 70,000-ton production lines, is scheduled to commence production in October 2026 (85% complete as of 2026H1); other-regions revenue was RMB 87 million in 2026H1, up +48.96% YoY, but accounts for only 5.65% of the total; ③ Related-party deposit balance has been reduced from RMB 3.124 billion (end-2025) to RMB 2.871 billion (end-2026H1), creating room for the governance discount to narrow.
Primary share price drivers: ① The true organic nature of almond milk growth — excluding the Spring Festival mismatch, Q2 organic revenue growth was only +4.9%; after the pull-forward effect fades in H2, full-year growth will depend on Q3/Q4 sell-through and peak-season stocking (leading indicators: Q3 single-quarter growth rate, whether operating cash flow turns positive, and a quarter-on-quarter rebound in contract liabilities); ② Southern national expansion × Chun'an capacity ramp-up — other-regions revenue is the only trackable hard metric for nationalization; ③ Shareholder return delivery — the FY2025 cash payout ratio of 81.3% (approx. 111% including buybacks in the period) and the 6.08% dividend yield form a valuation floor; dividend policy and deposit disposition are the switch governing the governance discount.
Verifiable expectation gap: Market pricing is sharply divided at both ends. The trading price implies "perpetual zero category growth + governance discount fully priced in" — the current price of RMB 8.22 approximates the zero-growth EPV (approx. RMB 8.3–8.5 with related-party deposits valued at a 50% discount), paying almost nothing for growth. Sell-side consensus, however, prices in "inflection point confirmed + nationalization growth" — FY2026 EPS of RMB 0.69 (implying true growth of approx. +12.2%), 17 covering analysts with no ratings below Neutral, and a median target price of RMB 12.1 (approx. +47% above the current price). Our own estimate (FY2026 net profit attributable to parent RMB 667–678 million, +6.3% to +8.1%) is about 4–5% below consensus, with the core disagreement on H2 organic growth and governance variables. Note: the relationship between the current price and EPV is highly sensitive to the "related-party deposit discount rate" parameter (EPV approx. RMB 9.8 at a 0% discount, approx. RMB 7.2 at a 100% discount); the "undervalued" conclusion is not robust to this parameter, and this report characterizes it as "reasonably cheap, but only modestly" rather than deeply undervalued.
Validation catalysts and falsification conditions: Catalysts — Chun'an plant start-up (October 2026), Q3 report (late October), earlier 2027 Spring Festival (2027-02-06, stocking shifted forward to 2026Q4), FY2026 dividend plan (April 2027), continued reduction of related-party deposits. Falsification — Q3 single-quarter revenue growth falling below 5% or persistently negative operating cash flow (recovery narrative disproven); Chun'an start-up delayed to 2027 (nationalization narrative downgraded); significant cut in payout ratio or rebound in deposit balance (both the dividend floor and the discount-narrowing logic invalidated simultaneously).
Key evidence:
The company is a near-monopoly manufacturer in the category (third-party estimates put its almond milk market share at approx. 90%; the company's periodic reports only state it is "the largest almond milk manufacturer in China" without disclosing a percentage — share data pending verification by authoritative sources). Its gross margin of 45–49% is significantly above peers (Huanleijia coconut milk 36%, VV Group plant protein 18%), and the payment-before-delivery model gives earnings high cash content (OCF/net profit attributable to parent of 0.98 / 0.95 / 1.61 for 2023–2025). Objectively, this is a gently declining platform — 2025 net profit attributable to parent fell -5.87%, 2025H1 revenue fell -15.3% YoY, and 2026H1 revenue of RMB 1.540 billion remains about 5.7% below 2024H1; the "recovery" is relative to the deep 2025 base. ROE has also declined from approx. 23.5% in 2022 to 18.1% in 2025.
Key evidence:
Using 2025 non-recurring EPS of RMB 0.61 and a WACC of 8.5%, the zero-growth EPV is approx. RMB 7.2/share (excluding cash) to RMB 8.3–8.5/share (including net cash valued at a 50% discount); valuing the related-party deposits in full gives an EPV of approx. RMB 9.8, and at zero, approx. RMB 7.2 — the current price of RMB 8.22 falls within this parameter range, and the "price ≈ EPV" conclusion is highly sensitive to the discount parameter. We therefore characterize the valuation as "reasonably cheap" rather than "significantly undervalued" (this report's calculated margin of safety is approx. +5%, probability-weighted expected value of RMB 9.16, implying expected return of approx. +11.4%). Independent price anchors: the dividend yield anchor (DPS of RMB 0.50–0.55 ÷ required return of 5.5–6% = RMB 8.7–9.5) and the 5-year median PE of 14.9x × 2026E EPS of RMB 0.65 ≈ RMB 9.7. Emphasis: the 6.08% dividend yield is a realized figure, not a commitment — DPS history of RMB 0.40 (FY2023) → RMB 0.30 (FY2024) → RMB 0.50 (FY2025) is highly volatile, and management has only said the 2026 dividend will be decided "based on operating conditions." Moreover, the high dividend coexists with a negative-carry structure of "low-rate deposits with an affiliate + interest-bearing bank borrowings" (annualized interest spread loss of approx. RMB 22 million, approx. 3.5% of net profit). With 2026H1 operating cash flow at -RMB 186 million, the cash sustainability of the high dividend needs Q3/Q4 collection to validate.
Key evidence:
The 2026 Spring Festival (February 17) fell significantly later than 2025's (late January), pushing stocking and revenue recognition later — depressing the 2025 annual results and inflating 2026Q1/H1 growth — consistent with the industry-wide mismatch seen at peer Yangyuan Beverage (2026H1 revenue +41.97%, but Q2 net profit at its worst in years). Excluding the mismatch, Q2 organic growth was only approx. +4.9%, and the two-year stacked growth remains negative. We estimate FY2026 net profit attributable to parent at RMB 667–678 million (+6.3% to +8.1%), implying H2 YoY growth of approx. 0% to +3% — a conservative assumption (assuming the mismatch benefit fades and the Mid-Autumn gifting season is steady); if Q3 sell-through beats expectations, the full year could approach consensus of RMB 700 million. Conversely, if Q3 growth falls below 5%, the "recovery" narrative would be falsified.
Key evidence:
Approx. RMB 2.871 billion of deposits (93% of cash and equivalents, approx. one-quarter of total assets) have long been parked at a non-bank financial institution under the same actual controller as the controlling shareholder, with yields declining year by year and below the company's own borrowing costs. The company received an SZSE inquiry letter over this in 2022, and market skepticism about Wanxiang as an "ATM" has persisted. The directly quantifiable financial damage is not large (negative carry of approx. RMB 22 million/year, approx. 3.5% of net profit); the essence of the discount is unquantifiable trust and tail-risk pricing — we do not offer a falsely precise discount percentage, only noting that this parameter swings per-share value by approx. RMB 1.3–1.6 (deposits valued at 50% vs 100%), making it the single largest swing variable in the valuation. A positive signal is that the deposit balance has begun to decline (RMB 3.124 billion → 2.871 billion). Other governance watch-list items: the vacant Board Secretary position, the December 2025 change of audit firm (Tianjian International resigned, replaced by RSM — reappointed in August 2026), and the failure of the second-phase equity incentive performance targets.
Key evidence:
The direction of southern expansion is real (H1 other-regions +48.96%, Jiangsu distributor network in place), but it must be priced soberly: the +49% growth contributes only approx. 2.8 percentage points to total revenue, and with southern expansion stalled for many years prior, the +49% lacks multi-year validation and cannot be distinguished as sell-in vs sell-through. The Chun'an start-up is currently a business plan and media report (85% complete), not an established fact. Second-curve narratives are being falsified: almond milk beverage revenue was only RMB 151,700 in H1, while wellness water revenue declined with gross margin down 14.4 percentage points. In addition, the Shantou Lolo trademark case ended with a final loss at second instance in January 2026 (Shantou Lolo holds trademark usage rights in 8 southern China provinces plus national exclusive production and distribution rights for Tetra Pak packaging), directly constraining South China execution — though the market also offers the opposite reading that "all disputes over a decade-plus concluded at final appeal = uncertainty cleared." We lean toward viewing this as a substantive constraint on South China expansion, but acknowledge both interpretations coexist.
| Metric | 2023FY | 2024FY | 2025FY | 2026H1 |
|---|---|---|---|---|
| Revenue (RMB 100M) | 29.55 | 32.87 | 31.74 | 15.40 |
| Revenue YoY | +9.76% | +11.26% | -3.46% | +11.29% |
| Net profit attributable to parent (RMB 100M) | 6.38 | 6.66 | 6.27 | 2.98 |
| Net profit attributable to parent YoY | — | +4.41% | -5.87% | +15.28% |
| Non-recurring net profit (RMB 100M) | 6.35 | 6.58 | 6.24 | 2.96 |
| Gross margin | 41.46% | 40.94% | 44.74% | 47.86% |
| Net margin | 21.60% | 20.27% | 19.76% | 19.34% |
| Operating cash flow (RMB 100M) | 6.27 | 6.30 | 10.12 | -1.86 |
| Free cash flow (RMB 100M) | 4.36 | 4.15 | 8.27 | — |
| Cash & cash-like assets (RMB 100M) | — | — | 40.32 (end-2025) | 33.03 (end-2026H1, incl. Ping An RMB 220M + short-duration bond ETF RMB 8M) |
| Interest-bearing debt (RMB 100M) | — | — | 5.92 (end-2025) | 6.95 (end-2026H1) |
| Debt-to-asset ratio | — | — | 34.28% | 25.10% |
| Contract liabilities (RMB 100M) | 2.48 | 1.57 | 2.05 | 0.41 |
| Number of distributors | 866 | 922 | 947 | 1,009 |
| Cash payout ratio | 64.5% | 47.3% | 81.3% (approx. 111% incl. buybacks in period) | No interim distribution |
Reasons for metric changes (items with YoY ≥ ±20%, per company official explanations):
2026H1 revenue was RMB 1.540 billion (+11.29%), net profit attributable to parent RMB 298 million (+15.28%), non-recurring net profit +14.51%; almond milk revenue +10.49% with gross margin rising to a record 49.39%, and fruit & nut walnut products +81.61%. Versus market expectations: sell-side consensus for FY2026 growth is approx. +12.2%; H1 completion (46% of revenue, 42% of net profit) looks on track, but structurally the Q1 +13.73% relied mainly on the Spring Festival mismatch catch-up, and Q2 organic growth was only +4.9%. H2 faces a relatively high 2025H2 base (2025H2 revenue of RMB 1.790 billion, +8.3% YoY). Two blemishes warrant caution: operating cash flow of -RMB 186 million diverging from profit growth, and period-end contract liabilities of only RMB 41 million (vs RMB 205 million at the start of the period — partly seasonal, but the decline is steep). Under the payment-before-delivery model, prepayments falling rather than rising means the quality of growth needs Q3/Q4 collection to validate; watch for channel stuffing. Overall judgment: the recovery is real but its quality needs verification — insufficient evidence to justify "beats" pricing.
Business model snapshot: A classic "hero product + distribution + gifting occasions" FMCG model — the almond milk single product accounts for 94% of revenue, distribution accounts for roughly 94% of revenue (about 99% on a distribution basis in 2026H1), payment before delivery, production driven by sales, no recurring/subscription revenue attribute, with demand highly tied to the Northern Spring Festival gifting season (Q1 is the absolute peak season). It has strong bargaining power over upstream suppliers (Chengde/Bashang wild apricot farmers, can manufacturers) and strong leverage over downstream distributors via receivables, but weak pricing power over end consumers (hero product pricing stable for years).
Cash conversion of earnings check: OCF/attributable net profit for 2023–2025 was 0.98 / 0.95 / 1.61, and FCF/attributable net profit was 0.68 / 0.62 / 1.32 — book profits essentially convert into real cash; the 2025 cash flow bumper year included a low-base effect from reduced cash paid for goods purchases. The negative OCF in 2026H1 (RMB -186 million) is the main blemish and needs to be validated by peak-season collections. The gap between non-recurring-adjusted and attributable profit has been <2% in all years, with no one-off profit window dressing; the company does not disclose any Non-GAAP measure, so there is no aggressive add-back issue.
Return on capital: Estimated ROIC is about 15.5% (2025, NOPAT/(net assets + interest-bearing debt), this report's own methodology), well above the assumed WACC of 8.5% — the category monopoly generates genuine excess returns. However, note that if the denominator includes RMB 2.871 billion of low-yield deposits, the return would be diluted; the true return on operating assets is higher. ROE declined from about 23.5% in 2022 to 18.1% in 2025 — a downward trend.
Maintenance CapEx scrutiny: CapEx/depreciation for 2023–2025 was 11.5 / 9.6 / 3.9 — during the expansion construction phase of the new 500,000-ton plant plus the Chun'an project, far above the 1.5 warning threshold, but this is growth investment rather than a maintenance black hole. As Chun'an comes onstream and CapEx declines (RMB 185 million in 2025), FCF has already strengthened (RMB 827 million in 2025). Key watch point: if capacity utilization at the 150,000-ton Chun'an plant ramps up slowly, depreciation (already +158.75% in 2025) will keep eroding profits.
Moat / red flags: Moat = brand (nearly 30 years of Northern gifting mindshare) + raw material origin (exclusive access to wild apricot growing regions) + category monopoly structure. Red flags: ① dual concentration of hero product + region (almond milk 94%, Northern region 90%); ② RMB 3.1 billion parked long-term at an affiliated finance company at a 1.28% yield below the company's own borrowing rate (KAM in the 2025 annual report); ③ in 2026H1, RMB 465 million used to buy Ping An Insurance shares with an unrealized loss of about RMB 80.54 million, contrasting with the controversy over its "deposit-for-safety" cash management style; ④ R&D expense ratio of only 0.29% and R&D headcount down from 105 to 51, inconsistent with the stated "product innovation system" strategy.
Words vs. deeds: ① At the September 2025 earnings briefing, management committed to completing the buyback within 12 months without extension → completed on schedule in November 2025, buying back 31.41 million shares for RMB 285 million and canceling them, fulfilled; ② 2025 annual report operating plan stated "Chun'an project to commence production in 2026" → 85% progress in 2026H1, two production lines expected onstream in October, in progress, partially fulfilled; ③ the second vesting-period performance targets of the 2024 restricted stock incentive plan → confirmed as not met in 2026, with 3.6 million shares repurchased and canceled, not fulfilled (reflecting 2025 results falling below the incentive target line). Overall verdict: largely pragmatic, but the missed incentive targets expose performance pressure.
Shareholder friendliness: Payout ratio of 64.5% → 47.3% → 81.3% for FY2023–2025 (cash basis; about 111% including the buyback in the period), with the FY2025 dividend raised sharply to RMB 5 per 10 shares; no equity dilution via new share issuance or rights offerings since listing, and two buyback-and-cancellations in 2023 and 2025. Verdict: shareholder friendliness has clearly improved, but DPS has historically been volatile (RMB 0.40 → 0.30 → 0.50) and management makes no commitments — the continuity of the high payout policy remains to be seen.
Risk signals: ① Large-scale, long-running related-party transactions — RMB 2.871 billion in deposits held at Wanxiang Finance and Wannaxin receivables certificates using the controlling shareholder's credit line (fully settled and closed in 2026H1, but deep related-party dependence); ② general manager change in 2025 (Liang Qichao departed, Ding Xingxian took over), full board re-election in May 2026, board secretary vacancy being covered by the chairman; ③ audit firm changed in December 2025 (Tianjian resigned → RSM, continuous tenure of only 1 year; reappointed in August 2026); ④ key management compensation plunged from RMB 20.24 million in 2024 (including share-based payment) to RMB 4.66 million in 2025. Overall: governance under observation — no proven violations, but structural related-party dependence is a long-term source of the valuation discount.
| Segment | 2025 Revenue Share | Gross Margin | YoY | Business Logic |
|---|---|---|---|---|
| Almond milk series | 94.17% | 45.45% | -6.25% | Absolute hero product; volume -7.75%; margin gains driven by cost declines |
| Nut & walnut series | 2.80% | 26.98% | +4.65% | Second category; gross margin significantly below core business |
| Water series (wellness water/sparkling water) | 2.62% | 41.71% | New | New 2025 launch ramping up, entering a high-growth segment |
| Almond milk beverage series | 0.36% | 25.35% | -5.69% (further -98% in 2026H1) | Essentially being wound down |
| Northern region | 90.31% | 46.08% | -4.15% | Traditional stronghold in North China |
| Central region | 5.72% | 34.24% | -4.96% | Small scale, relatively low gross margin |
| Other regions (South) | 3.97% | 29.49% | +18.66% (+48.96% in 2026H1) | Expansion phase, heavy investment and low margin |
Profit engine: The almond milk series, with 94.17% of revenue at a 45.45% gross margin, contributes virtually all gross profit — the only profit-driving segment. Gross margin structure spread: the gap between the highest (almond milk 45.45%) and the lowest (almond milk beverage 25.35%) is about 20 percentage points — essentially the difference between category-monopoly pricing power and competitive new products. The South's 29.49% gross margin is well below the North's 46.08%, reflecting expansion-phase investment and diseconomies of scale — a rising Southern revenue share will dilute overall gross margin in the near term; this is a hidden cost of national expansion.
Accounting red flags:
Cross-period consistency:
Current market data and certainty-multiple percentile (closing price RMB 8.22, 2026-08-31; market cap RMB 8.384 billion): PE(TTM) 12.6x — 14th percentile over 1 year / 11th over 3 years / 6th over 5 years / 3rd over 10 years; static PE 13.4x (17th percentile over 5 years); PB 2.6x — 73rd percentile over 1 year / 37th over 3 years / 22nd over 5 years; dividend yield 6.08%. Earnings representativeness largely holds (the -5.07% decline in 2025 non-recurring-adjusted profit is normal volatility for a mature category, not a cyclical trough; but the TTM basis lags the 2026H1 recovery). Liquidity is normal (average daily turnover about 2–3% of market cap) — not a low-liquidity name.
Peer comparison:
| Company | PE(TTM) | PB | 2025 Revenue Growth | 2026H1 Revenue Growth | ROE | Key Differences |
|---|---|---|---|---|---|---|
| Chengde Lolo | 12.6 | 2.60 | -3.46% | +11.29% | 18.1% | Category monopoly, high dividend, governance discount |
| Yangyuan Beverage | 39.4 | 6.15 | -11.91% | +41.97% | 13.2% | 1.7x Lolo's size; premium for Red Bull agency as second growth curve |
| Huanle Jia | 149.1 (distorted) | 7.46 | -19.1% | -1.7% | 4.05% | Earnings collapse distorts PE; 29.9% gross margin far below Lolo |
| VV Group | 15.0 | 1.45 | -8.42% | +9.54% | 9.4% | Closest low-valuation comparable, but far lower ROE/gross margin |
| Eastroc Beverage | 18.0 | 4.52 | +31.80% | +15.9% | 51.6% | High-growth soft drink benchmark; the growth gap is a fair part of the discount |
The combination of 2.6x PB (low-to-mid percentile) with 18.1% ROE (high percentile among peers) shows the market is discounting both its earnings sustainability and its governance.
Market-implied expectations: The current price of RMB 8.22 = 13.4x 2025 non-recurring-adjusted EPS; ex-net cash, EV/adjusted earnings is about 9.3x (full net cash basis). Backing out at a WACC of 8.5%, the current price approximates an EPV of "zero perpetual earnings growth + RMB 2.871 billion of related-party deposits valued at roughly half" — the market pays essentially nothing for growth from Southern expansion, new categories, or Chun'an capacity. Yet the reality is: 2026H1 adjusted profit +14.51%, still +4.9% organically in Q2 even after stripping the timing mismatch, gross margin of 47.9% at a high, and ROIC of about 15.5% far above WACC. This is a classic case of "governance discount overwhelming fundamentals": the current price demands perpetual zero growth, while reality is better than zero growth but worse than the sell side's +12.2%.
Three-layer value (EPV): The asset value floor is about RMB 1.75/share (book BVPS RMB 3.16, after discounting related-party deposits); zero-growth EPV is about RMB 8.3–8.5/share (normalized EPS RMB 0.61 = 2025 adjusted profit of RMB 624 million ÷ 1.021 billion shares, WACC 8.5%, net cash at 50% = RMB 1.15/share; sensitivity: about RMB 9.8 at 0% deposit discount, about RMB 7.2 at 100%); the current price is mainly supported by the zero-growth earning-power layer, and the value of the growth option cannot be precisely measured within parameter noise — the market prices growth extremely low, but the precise claim "growth option = 0" is not robust. EPV of RMB 8.3 ≫ asset value of RMB 1.75 — the moat premium (category monopoly + 15.5% ROIC) is clear.
Three scenarios and odds (probabilities are this report's own judgment):
| Scenario | Fair Value Range | vs. Current Price | Probability | Key Drivers |
|---|---|---|---|---|
| Bear | RMB 7.0–7.5 | -14.8% ~ -8.8% | 30% | Category decline continues (revenue back below -3%) + Southern expansion fails + payout cut/widening deposit discount; the swing factor is the payout — as long as the high payout holds, a 6%+ dividend yield forms a hard floor |
| Base | RMB 8.6–9.5 | +4.6% ~ +15.6% | 50% | Low-single-digit growth delivered (adjusted profit RMB 660–680 million) + payout maintained at 80–100% + no widening of the governance discount; dividend yield anchor and EPV corroborate each other |
| Bull | RMB 11.5–13.1 | +39.9% ~ +59.4% | 20% | Southern market breakthrough + new category ramp + Chun'an at full capacity; adjusted profit climbs to RMB 800–840 million in 2027–2028, at a 15–16x exit PE (a discount to Eastroc's current 18.0x and Yangyuan's 5-year median PE of 18.6x) |
The current price of RMB 8.22 sits above the bear case but below the lower edge of the base range; the odds are asymmetrically positive (downside -14.8%~-8.8% vs. base upside +4.6%~+15.6% and bull +39.9% or more), but the base case's margin of safety is only about +5% (vs. the lower bound) — "reasonably cheap" rather than deeply undervalued. Bear-case anchor check: the most pessimistic published forecast is 2026 net profit of RMB 675 million (lowest among 4 covering brokers, implying +7.7%), which at 12x implies about RMB 7.9 — this report's bear case (RMB 7.0–7.5) is more pessimistic than the entire sell side, additionally embedding category-decline and payout-cut risks; the base range (RMB 8.6–9.5) sits between the most pessimistic sell-side implied value (about RMB 7.9) and the most optimistic target price (RMB 12.07), a reasonable anchoring position. Base-case exit multiple anchors: the dividend yield anchor (RMB 0.50–0.55 DPS ÷ 5.5–6% required return = RMB 8.7–9.5) and the EPV (0.65 ÷ 8.5% + 1.15 ≈ RMB 8.8) corroborate each other, both independent of the company's current trading multiples; the 5-year median PE of 14.9x × RMB 0.65 ≈ RMB 9.7 serves as an upper-bound reference.
Own earnings forecast (side by side with management guidance and sell-side consensus):
| Basis | FY2026E | Rationale |
|---|---|---|
| This report | Revenue RMB 3.33–3.38 billion (+4.9%~+6.6%); attributable net profit RMB 667–678 million (+6.3%~+8.1%); adjusted profit RMB 662–673 million | H1 already locked in +11.29%; H2 assumed at 0~+3% (timing mismatch fading; Q2 organic +4.9% as trend anchor); full-year gross margin about 46.5%; implied H2 attributable profit growth about 0%~+3% |
| Sell-side consensus | EPS RMB 0.69 (attributable profit about RMB 704 million, +12.2%); FY2027 EPS RMB 0.75 | 17 covering brokers, +2.2% upward revision in 90 days; implies H2 attributable profit +10.1% |
| Management guidance | No quantitative targets disclosed | Qualitative statements: deepen Northern market penetration + develop Southern markets, omnichannel penetration, ensure Chun'an capacity comes onstream |
Biggest uncertainties: the H2 base (2025H2 revenue of RMB 1.79 billion was 56% of the full year) and gross margin sustainability (47.9% depends on tinplate/sugar prices).
Conclusion: Reasonably cheap. Assess quality and price separately — quality is excellent (category monopoly, high gross margin, high ROIC, high dividend); the price is reasonably cheap but only modestly so (margin of safety about +5%); target price range RMB 8.6–9.5. Until the governance discount is removed, a re-rating toward the RMB 12 consensus target lacks a trigger; the path to valuation recovery only opens if deposit reduction continues + dividend policy is clarified + Q3 results confirm growth.
Market Size: The segment where the company truly competes is the almond milk category within plant-based protein beverages. Macro data: per Euromonitor, China's plant-based protein beverage market was about RMB 53.69 billion in 2019, with a 2019–2024 CAGR of only about 2.7%; industry reports show growth in 2025 has slowed to about 1.2%, and MaShangYing data indicates plant-based protein beverages were the second-fastest declining beverage category by sales growth in 2025 (behind only milk-containing beverages). The almond milk sub-category is roughly RMB 3.5 billion in size (2021, per Huaxi Securities research, to be verified), a small share of the total market. Over the next 3–5 years, the category is expected to maintain a low single-digit CAGR of 0–3%: it has entered maturity, with volume growth stalled and value sustained by structural upgrades (low-sugar/sugar-free, small packaging) and gifting occasions. For comparison against the broader soft drink market: Eastroc Beverage's 2025 revenue was RMB 20.875 billion, +31.8%, with electrolyte water up +119%—incremental demand is clearly flowing toward functional/health-oriented categories, while traditional high-sugar plant-based protein beverages are losing share. No authoritative institution's explicit 2026–2030 CAGR forecast is available (not obtained).
Value Chain and Value Distribution: Upstream is agricultural raw materials (almonds, walnuts, coconut, white sugar) and packaging materials (tinplate three-piece cans, Tetra Pak cartons)—Chengde Lolo relies on the wild apricot growing region of Chengde/Bashang, procuring from dispersed farmers/cooperatives, giving it regional exclusivity and strong bargaining power; midstream is production + branding (grinding, blending, UHT, filling), where technical barriers are not high but economies of scale and brand recognition are the moats, and gross margin is mostly retained at this stage (Lolo almond milk 45–49%, Yangyuan walnut milk about 47%, Huanlejia coconut juice 36–40%, all far above upstream); downstream is the distribution system (distribution accounts for about 99% of Lolo's sales) → supermarkets/general trade/e-commerce → consumers. The company uses a payment-before-delivery/advance-collection model, occupying downstream funds and holding strong bargaining power, but channel profit margins are limited and distributor motivation depends on rebates and advertising support (2025 selling expenses of RMB 534 million, +27.59%); nationwide expansion requires ceding margin to distributors. The company occupies a favorable position in value distribution, but has weak bargaining power over end consumers.
Supply-Demand and Competitive Landscape: Demand side—northern holiday gifting is the base, while daily-consumption penetration is low; insufficient penetration in the South and among younger consumers is the main incremental opportunity (and also a persistent challenge). Pricing headroom is limited, so upgrades rely on low-sugar versions/small packages/new products. Supply side—stable players, no capacity expansion wave: almond milk has essentially only Chengde Lolo as a scaled player; walnut milk is dominated by Yangyuan; coconut juice has Yeshu/Huanlejia/Yetai/Fino; oat milk has Oatly and domestic substitutes. The industry has no overcapacity problem—the problem is insufficient demand. Concentration—extremely high within each category but the market is fragmented: Lolo holds about 90% of the almond milk category (per the company and multiple long-standing sources, by retail sales value, to be verified; the company's periodic reports only claim "largest in China"); Yangyuan is the absolute leader in walnut milk (2025 walnut milk revenue of RMB 4.43 billion); the plant-based protein beverage market overall CR3 is estimated at 30–40% (estimated from Euromonitor 2019 market size and individual companies' revenues, to be verified). Entry barriers—brand recognition (accumulated over 20–30 years), raw material origins, nationwide distribution network, scale-driven cost advantages. New entrants can enter new categories via asset-light contract manufacturing, but can hardly shake established hero products. Competitive intensity—mild within traditional categories (each defends its own product, few price wars), but under fierce diversion from new categories within the broader soft drink market: sugar-free tea, electrolyte water, and RTD coffee are growing rapidly; within coconut juice there is price competition (Huanlejia raised prices 1–8% in July 2025 to offset gross margin decline). Substitution threats are significant and ongoing: oat milk and thick coconut milk in freshly-made tea/coffee are replacing the "healthy/fashionable" positioning; sugar-free tea, electrolyte water, and wellness water are diverting gifting and self-consumption budgets; room-temperature yogurt competes directly in gifting occasions; almond milk is high in sugar and heavy on the palate, making it less appealing to younger consumers.
Cyclicality and Regulation: The industry has no strong cyclicality, but its gifting attribute makes performance highly seasonal—the timing of Chinese New Year is the biggest "cyclical" variable (the late 2026 CNY pressured the 2025 annual report and boosted 2026H1; the early 2027 CNY on February 6 will pull forward stocking into 2026Q4). Leading indicators: CNY timing, hero-product sales volume and inventory (Lolo's 2025 inventory +33.08% is a warning signal), intensity of selling expense deployment, tinplate/white sugar/almond purchase prices, and the pace of new product ramp-up. Regulation—GB 7718-2025 (General Rules for Labeling of Prepackaged Foods) and GB 28050-2025 (General Rules for Nutrition Labeling of Prepackaged Foods) take effect March 16, 2027: mandatory labeling of allergens (almonds are among the eight major allergens), and mandatory "children and adolescents should avoid excessive intake of salt, oil, and sugar" warnings on nutrition facts panels; the "Healthy China 2030" sugar-reduction orientation poses medium-term pressure on high-sugar almond milk. The direction is neutral to slightly favorable for leading players: compliance costs rise, but small workshops exit and concentration rises, forcing low-sugar formula upgrades (the company has launched low-sugar products and a wellness water series).
Peer Benchmarking (the company's own data presented on a financial-report basis):
| Company | 2025 Revenue | Revenue Growth | Gross Margin | ROE | Scale Ranking | Key Differences vs. Lolo |
|---|---|---|---|---|---|---|
| Chengde Lolo | RMB 3.174 bn | -3.46% | 44.74% | 18.1% | #1 in almond milk (about 90%) | Category monopoly but doubly concentrated by region and occasion |
| Yangyuan Beverage | RMB 5.336 bn | -11.91% | 46.91% (walnut milk) | 13.2% | Absolute leader in walnut milk | 1.7x Lolo's scale, Red Bull distribution as second curve, more aggressive marketing |
| Huanlejia | ~RMB 1.26 bn (coconut juice + canned foods) | Coconut juice -21.51% | 29.59% | 4.05% | Second tier in coconut juice | Coconut-based products pose substitution threat to almond milk; upstream integration (Indonesian coconut supply) |
| VV Group | RMB 3.349 bn | -8.42% | 26.32% | 9.4% | Leader in soy milk powder | Liquid plant protein only RMB 341 million, gross margin 18.48%, far lower earnings quality |
| Eastroc Beverage | RMB 20.875 bn | +31.80% | — | 51.6% | #1 in energy drinks | Benchmark of the high-growth direction in soft drinks: functional, youthful, nationwide |
Company's Position in the Industry: The absolute leader in the almond milk category (stable share within the category), but a niche player in both the plant-based protein beverage market and the broader soft drink market (2025 revenue is about 60% of Yangyuan's and 15% of Eastroc's). The share trend shows "stable within category, declining within market": almond milk 2025 sales volume of 304,900 tons (-7.75%), inventory +33.08%, with the category being diverted by coconut-based/oat-based and functional new categories. Sources of moat: brand (nearly 30 years of gifting mindshare in the North), raw material origin (exclusive access to wild apricot growing regions), channel (payment-before-delivery distribution system), and high earnings quality. The core bottleneck is dual concentration by region and occasion (northern region accounted for 88.57% in 2026H1); nationwide expansion has not broken through for years. The response is the Chun'an base (production start October 2026) to radiate the South, plus entry into new categories like wellness water/sparkling water (2025 revenue of RMB 83.12 million—growing fast but small). Overall judgment: a cash-cow category monopolist—strongly defensive but lacking growth; a "mature niche leader," not a growth stock.
Dimensions that generic beverage industry frameworks often miss:
Overall Assessment: Chengde Lolo is a high-quality, reasonably-to-modestly undervalued monopolistic cash cow—category monopoly (about 90% share in almond milk, third-party data to be verified), gross margin 47.9%, ROIC about 15.5%, dividend yield 6.08%, PE (TTM) at the 6th percentile of the past 5 years; but two constraints remain unresolved—governance discount (RMB 2.871 billion related-party deposits) and long-term category demand pressure. 2026H1 growth contains CNY-timing distortion (Q2 organic growth only +4.9%), and the base-case margin of safety is only about +4.6%. We assign a Neutral rating (stance: neutral, confidence 0.55), over a 12–18 month horizon: the current price sits near the lower edge of base-case fair value (RMB 8.6–9.5), with asymmetric but positive odds yet lacking an upward catalyst—stay on the sidelines; existing holders can patiently await marginal governance improvement, supported by the 6% dividend yield.
Strategy Implications: ① Left-side investors should watch three validation points—continuity of Q3 report growth (Q3 single-quarter growth ≥10%, operating cash flow turning positive, contract liabilities rebounding), delivery of Chun'an production start in October, and clarity on the 2026 annual dividend policy; ② any validated point allows an upgrade to Positive, targeting the base-case center of RMB 9.0 or even bull-case recovery; ③ falsification signals—Q3 growth falling below 5%, a significant cut in payout ratio, or a rebound in deposit balances—would warrant a downgrade to the bear case of RMB 7.0–7.5 for valuation.
Risk Disclosures: Safety of related-party deposits and governance risk (low-probability, high-impact tail risk); continued category decline and substitution/diversion (highest-probability risk); southern expansion and Chun'an ramp-up falling short of expectations; rising raw material costs (wild apricot kernels, white sugar, tinplate); observation-period risk from management transition and the vacant board secretary position; constraints on South China from the Shantou Lolo trademark case.
Key Monitoring List: ① Balance of "deposits with finance company" in each periodic report (currently RMB 2.871 billion) and Wanxiang Finance's regulatory metrics; ② Q3/Q4 almond milk sales volume, inventory, and contract liabilities; ③ revenue growth in other regions and the number of southern distributors; ④ 2026 annual dividend proposal and whether a new round of share buyback is launched; ⑤ share of sugar-free/low-sugar SKUs and wellness water revenue growth; ⑥ appointment of the new board secretary and internal control audit opinions.
Primary sources: Chengde Lolo 2023/2024/2025 annual reports, 2026 semi-annual report and Q1 report, Wanxiang Finance risk assessment report (2026-08-15), excerpts from Shenzhen Stock Exchange investor Q&A (2026-08-25), investor relations activity records (2025-09-15), and public coverage from 10jqka/Time Finance/The Economic Observer. Valuations in this report are anchored to the closing price of RMB 8.22 on 2026-08-31.